Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States

Objective: To evaluate annual concomitant psychotropic medication use among stimulant-treated children/adolescents with ADHD. Method: Children/adolescents with ≥1 primary ADHD diagnosis who had received ≥30 days of stimulant medication were identified from insurance claims for each calendar year (20...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhou, Betts, Keith A., Bocharova, Iryna, Kinrich, David, Spalding, William M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939321/
https://www.ncbi.nlm.nih.gov/pubmed/29991300
http://dx.doi.org/10.1177/1087054718784668
_version_ 1783484193797308416
author Zhou, Zhou
Betts, Keith A.
Bocharova, Iryna
Kinrich, David
Spalding, William M.
author_facet Zhou, Zhou
Betts, Keith A.
Bocharova, Iryna
Kinrich, David
Spalding, William M.
author_sort Zhou, Zhou
collection PubMed
description Objective: To evaluate annual concomitant psychotropic medication use among stimulant-treated children/adolescents with ADHD. Method: Children/adolescents with ≥1 primary ADHD diagnosis who had received ≥30 days of stimulant medication were identified from insurance claims for each calendar year (2011-2014). Use of 15 psychotropic medications concomitantly with stimulants was evaluated and their prevalence in each year was calculated overall and by medication category for children (6-12 years) and adolescents (13-17 years). Results: Each year 133,354 to 157,303 children and 95,632 to 111,280 adolescents were included. Annual period prevalence of any concomitant psychotropic medication use was 22.9% to 25.0% for children and 25.2% to 28.2% for adolescents. The most common medication categories included selective serotonin reuptake inhibitors (children: 6.8%-7.9%; adolescents: 12.7%-14.9%), atypical antipsychotics (4.2%-5.4%; 5.3%-6.3%), and guanfacine extended release (5.1%-7.0%; 2.3%-3.6%). Conclusion: Around a quarter of children/adolescents with ADHD were prescribed psychotropic medication concomitant to stimulant treatment, although only 2 of the 15 medication classes studied were Food and Drug Administration (FDA)-approved for adjunctive use.
format Online
Article
Text
id pubmed-6939321
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-69393212020-02-07 Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States Zhou, Zhou Betts, Keith A. Bocharova, Iryna Kinrich, David Spalding, William M. J Atten Disord Articles Objective: To evaluate annual concomitant psychotropic medication use among stimulant-treated children/adolescents with ADHD. Method: Children/adolescents with ≥1 primary ADHD diagnosis who had received ≥30 days of stimulant medication were identified from insurance claims for each calendar year (2011-2014). Use of 15 psychotropic medications concomitantly with stimulants was evaluated and their prevalence in each year was calculated overall and by medication category for children (6-12 years) and adolescents (13-17 years). Results: Each year 133,354 to 157,303 children and 95,632 to 111,280 adolescents were included. Annual period prevalence of any concomitant psychotropic medication use was 22.9% to 25.0% for children and 25.2% to 28.2% for adolescents. The most common medication categories included selective serotonin reuptake inhibitors (children: 6.8%-7.9%; adolescents: 12.7%-14.9%), atypical antipsychotics (4.2%-5.4%; 5.3%-6.3%), and guanfacine extended release (5.1%-7.0%; 2.3%-3.6%). Conclusion: Around a quarter of children/adolescents with ADHD were prescribed psychotropic medication concomitant to stimulant treatment, although only 2 of the 15 medication classes studied were Food and Drug Administration (FDA)-approved for adjunctive use. SAGE Publications 2018-07-10 2020-01 /pmc/articles/PMC6939321/ /pubmed/29991300 http://dx.doi.org/10.1177/1087054718784668 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Articles
Zhou, Zhou
Betts, Keith A.
Bocharova, Iryna
Kinrich, David
Spalding, William M.
Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
title Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
title_full Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
title_fullStr Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
title_full_unstemmed Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
title_short Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States
title_sort concomitant use of psychotropic medication with stimulants for the treatment of adhd in children and adolescents: a retrospective insurance claims study in the united states
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939321/
https://www.ncbi.nlm.nih.gov/pubmed/29991300
http://dx.doi.org/10.1177/1087054718784668
work_keys_str_mv AT zhouzhou concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates
AT bettskeitha concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates
AT bocharovairyna concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates
AT kinrichdavid concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates
AT spaldingwilliamm concomitantuseofpsychotropicmedicationwithstimulantsforthetreatmentofadhdinchildrenandadolescentsaretrospectiveinsuranceclaimsstudyintheunitedstates